Skip to content

Does the presence of antibodies to SARS-CoV-2 reduce the risk of subsequent COVID-19 in healthcare workers?

Sarscov2 Immunity & REinfection EvaluatioN: Impact of detectable anti-SARS-COV2 on the subsequent incidence of COVID-19 in healthcare workers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN11041050
Enrollment
10000
Registered
2021-01-12
Start date
2020-06-18
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)

Interventions

Upon enrolment, participants will complete an online questionnaire and provide a blood sample for antibody testing and swabs for viral testing. Thereafter, every two to four weeks participants will b

Sponsors

UK Health Security Agency
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hospital healthcare worker willing to consent for regular follow up for 12 months with swabs and blood samples

Exclusion criteria

Exclusion criteria: Unwilling to participate in regular follow up

Design outcomes

Primary

MeasureTime frame
1. SARS-CoV-2 antibody measured in NHS laboratories using local assays (Roche Cobas or Abbott Platforms) measured monthly 2. SARS-CoV-2 infection measured using PCR test using local assays measured every two weeks

Secondary

MeasureTime frame
1. Symptoms of SARS-Cov-2 infection measured by a 2 weekly survey of participants developed and validated by study team including the 12 most commonly reported symptoms 2. Ability to culture viable virus from SARS-CoV-2 residual viral samples that are PCR positive submitted to PHE throughout the study, cultured in category 3 laboratory on vero cells 3. Identification of reinfection or persistent infection if second positive test after 90 days measured using SARS-CoV-2 viral RNA submitted to COG-UK sequencing laboratories for each positive PCR result 4. Serological response measured using SARS-CoV-2 residual positive sera submitted to PHE and measured using laboratory assays monthly 5. Serological response measured using enzyme immunoassay detection of IgG measured using laboratory assays monthly 6. NHS Trust, age, sex, staff group, ethnicity and co-morbidities as recorded by the participant recorded at baseline using a novel questionnaire 7. Phylogenetic relatedness of SARS-CoV-2 whole genome sequences on positive PCR samples, linked to MRC CLIMB in a secure data infrastructure with other samples submitted from hospitals and community in the same time period

Countries

England, United Kingdom

Contacts

Public ContactVictoria;Angela Hall;Dunne

;

siren@ukhsa.gov.uk;Angela.Dunne@ukhsa.gov.uk-;-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 11, 2026